RT Journal Article
SR Electronic
T1 Molecular surveillance reveals widespread colonisation by carbapenemase and extended spectrum beta-lactamase producing organisms in neonatal units in Kenya and Nigeria
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.06.22268735
DO 10.1101/2022.01.06.22268735
A1 Thomas Edwards
A1 Christopher T Williams
A1 Macrine Olwala
A1 Pauline Andang’o
A1 Walter Otieno
A1 Grace N Nalwa
A1 Abimbola Akindolire
A1 Ana I Cubas-Atienzar
A1 Toby Ross
A1 Kemi Tongo
A1 Emily R Adams
A1 Helen Nabwera
A1 Stephen Allen
YR 2022
UL http://medrxiv.org/content/early/2022/01/10/2022.01.06.22268735.abstract
AB Objectives Neonatal sepsis, a major cause of death amongst infants in sub-Saharan Africa, is often gut derived. Impairments in immunity and the gut barrier in sick neonates allow colonisation by opportunistic pathogens such as Enterobacteriaceae to progress to blood stream infection. Colonisation by Enterobacteriaceae producing extended spectrum beta-lactamase (ESBL) or carbapenemase enzymes is particularly problematic and can lead to antimicrobial-resistant (AMR) or untreatable infections. We sought to explore the rates of colonisation by ESBL or carbapenemase producers and their genotypes in two neonatal units (NNUs) in West and East Africa.Methods Stool and rectal swab samples were taken at multiple timepoints from newborns admitted to the NNUs at the University College Hospital, Ibadan, Nigeria and the Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu, western Kenya. Samples were tested for ESBL and carbapenemase genes using a previously validated qPCR assay with high resolution melt analysis. Kaplan-Meier survival analysis was used to examine colonisation rates at both sites.Results A total of 119 stool and rectal swab samples were taken from 42 infants admitted to the two NNUs. Six (14.3%) infants were extremely preterm (gestation <28 weeks), 19 (45.2%) were born by Caesarean section and 3 (8.6%) mothers were HIV positive. Median (IQR) duration of admission was 12.5 (5-26) days and 12 (28.6%) infants died. Overall, colonisation with ESBL (37 infants, 89%) was more common than with carbapenemase producers (26, 62.4%; P = 0.093). Median survival time before colonisation with ESBL organisms was 7 days and with carbapenemase producers 16 days (P=0.035). The majority of ESBL genes detected belonged to the CTX-M-1 (36/38; 95%), and CTX-M-9 (2/36; 5%) groups. The most prevalent carbapenemase was blaNDM (27/29, 93%). Single blaVIM (1/32, 3%) and blaOXA-48 genes (1/32, 3%) were also detected.Conclusions Gut colonisation of neonates by AMR organisms was common and occurred rapidly in NNUs in Kenya and Nigeria. Active surveillance of colonisation will improve the understanding of AMR in these settings and guide infection control and antibiotic prescribing practice to improve clinical outcomes.HighlightsColonisation with extended spectrum beta-lactamase (ESBL) or carbapenemase producing bacteria was common in two neonatal units in Kenya and NigeriaESBL colonisation occurred in 89% of neonates, with a median colonisation time of 7 daysColonisation with carbapenemase producers occurred in 62% of neonates, with a median time to colonisation of 16 daysThe most common ESBL genes detected were of the CTX-M-1 family, whilst the most common carbapenemase detected was blaNDMCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the MRC Confidence in Global Nutrition and Health Research Institutional pump-priming award 2018-2020 (MC_PC_MR/R019789/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Liverpool School of Tropical Medicine Research Ethics Committee (study number 18-021), the University of Ibadan/University College Hospital Ethics Committee (UI/EC/18/0446) and the JOOTRH Ethics Review Committee (ERC.IB/VOL.1/510).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors